» Articles » PMID: 38024854

Solid Phase Microextraction for Therapeutic Monitoring and Pharmacometabolomic Fingerprinting of Lung During Lung Perfusion of FOLFOX

Overview
Journal J Pharm Anal
Specialty Chemistry
Date 2023 Nov 29
PMID 38024854
Authors
Affiliations
Soon will be listed here.
Abstract

In vivo lung perfusion (IVLP) is a novel isolated lung technique developed to enable the local, in situ administration of high-dose chemotherapy to treat metastatic lung cancer. Combination therapy using folinic acid (FOL), 5-fluorouracil (F), and oxaliplatin (OX) (FOLFOX) is routinely employed to treat several types of solid tumours in various tissues. However, F is characterized by large interpatient variability with respect to plasma concentration, which necessitates close monitoring during treatments using of this compound. Since plasma drug concentrations often do not reflect tissue drug concentrations, it is essential to utilize sample-preparation methods specifically suited to monitoring drug levels in target organs. In this work, in vivo solid-phase microextraction (in vivo SPME) is proposed as an effective tool for quantitative therapeutic drug monitoring of FOLFOX in porcine lungs during pre-clinical IVLP and intravenous (IV) trials. The concomitant extraction of other endogenous and exogenous small molecules from the lung and their detection via liquid chromatography coupled to high resolution mass spectrometry (LC-HRMS) enabled an assessment of FOLFOX's impact on the metabolomic profile of the lung and revealed the metabolic pathways associated with the route of administration (IVLP vs. IV) and the therapy itself. This study also shows that the immediate instrumental analysis of metabolomic samples is ideal, as long-term storage at -80 °C results in changes in the metabolite content in the sample extracts.

Citing Articles

Pipette-tip solid-phase extraction coupled with matrix-assisted laser desorption/ionization mass spectrometry enables rapid and high-throughput analysis of antidepressants in rat serum.

Sun Z, Wang F, Li W, Ren R, Zhou P, Jia Q Anal Bioanal Chem. 2024; 416(22):5013-5023.

PMID: 38997460 DOI: 10.1007/s00216-024-05439-x.


Mapping the metabolic responses to oxaliplatin-based chemotherapy with spatiotemporal metabolomics.

Olkowicz M, Ramadan K, Rosales-Solano H, Yu M, Wang A, Cypel M J Pharm Anal. 2024; 14(2):196-210.

PMID: 38464782 PMC: 10921245. DOI: 10.1016/j.jpha.2023.08.001.

References
1.
Chambers M, MacLean B, Burke R, Amodei D, Ruderman D, Neumann S . A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012; 30(10):918-20. PMC: 3471674. DOI: 10.1038/nbt.2377. View

2.
Alcindor T, Beauger N . Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1):18-25. PMC: 3031353. DOI: 10.3747/co.v18i1.708. View

3.
Straw J, Szapary D, Wynn W . Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res. 1984; 44(7):3114-9. View

4.
Danenberg P, Gustavsson B, Johnston P, Lindberg P, Moser R, Odin E . Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action. Crit Rev Oncol Hematol. 2016; 106:118-31. DOI: 10.1016/j.critrevonc.2016.08.001. View

5.
Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer J . How can we best monitor 5-FU administration to maximize benefit to risk ratio?. Expert Opin Drug Metab Toxicol. 2018; 14(12):1303-1313. DOI: 10.1080/17425255.2018.1550484. View